A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether the use of prophylactic perioperative thyroxine therapy during cardiopulmonary bypass in the euthyroid adult patient undergoing routine cardiac surgery can result in an improved cardiac output leading to better clinical outcomes. Altogether 86 papers were identified on Medline and 113 on Embase using the reported search. A further paper was identified by hand-searching of reference lists. Thirteen papers represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that it is clear that triiodothyronine levels decrease by 50% or more during cardiopulmonary bypass. However, there is conflicting evidence that prophylactic perioperative thyroxineytriiodothyronine therapy is a useful inotropic adjunct in adult patients undergoing routine cardiac surgery and whilst some studies report improved haemodynamic parameters in the immediate post-bypass period there is no evidence that its use influences postoperative morbidity, mortality or length of stay in the elective patient. It may, however, have a role as rescue therapy in supporting some high risk cases during weaning from CPB or bridging to LVAD or transplant.
Introduction
A best evidence topic was constructed according to the structured protocol. This protocol is fully described in the ICVTS w1x.
Clinical scenario
You are anaesthetising a high risk CABG patient. Before coming off bypass, the surgeon requests that you give some thyroxine. You have never heard of this strategy before and thus, while you give the thyroxine, you decide to review the literature to see if there is any evidence to back up this strategy.
Three-part question
In wpatients undergoing cardiac surgeryx, is the use of wthyroxinex associated with wimproved cardiac output, better recovery or fewer complicationsx. 
Search strategy

Search outcome
A total of 86 papers on Medline and 113 on Embase were identified using the reported search. A further relevant paper was identified by hand searching reference lists. Thirteen papers represented the best evidence on the subject and are summarised in Table 1 .
Results
It is well recognised that decreased thyroxine hormone levels accompanying cardiopulmonary bypass (CPB) can be Downloaded from https://academic.oup.com/icvts/article-abstract/5/2/166/679553 by guest on 18 December 2018 reversed by thyroxine or triiodothyronine (T3) administration before or during bypass w2-6x. But whilst some studies have shown that this strategy can improve cardiac output there is little evidence that recovery is enhanced and complications decreased. Several authors have identified some short-term haemodynamic benefits following T3 or thyroxine administration during cardiac surgery. Sirlak et al. gave oral T3 both preoperatively and postoperatively and found significant differences in cardiac index (CI) and systemic vascular resistance (SVR) with decreased inotrope and IABP requirements w2x. But whilst ITU stay was less, there was no significant difference in myocardial ischaemiayinfarction rate, atrial fibrillation or death. Novitsky et al. found T3 administration on bypass decreased inotrope and diuretic requirement in patients with ejection fraction (EF) less than 30% although there was no difference in haemodynamic data w3x. Their T3 regime was subsequently modified on the basis of data from this study and repeated in patients with higher ejection fractions. Whilst there was no difference in inotrope or diuretic use in this latter group, cardiac output (CO) was significantly higher and SVR and pulmonary vascular resistance (PVR) lower in their T3-treated group w3x. Mullis-Jansson et al. reported similar improvements in CI in their male cohort following T3 administration at crossclamp release although both sexes experienced decreased myocardial ischaemia, inotrope dependenceyrequirement and need for mechanical support w7x. However, their control group was significantly older than their T3-group possibly confounding some of their findings w7x. Finally, Klemperer et al. noted that T3 administration in patients with impaired LV function significantly increased CI and decreased SVR for the first 6 h post-cross clamp removal w4x but found no significant differences in interventions required to support separation from CPB, postoperative inotrope use, duration of postoperative ventilation, ITU or hospital stay, or overall morbidity and mortality. However, whilst this study demonstrated comparable incidences of supraventricular and ventricular dysrhythmias in the first 18 h a subsequent paper by the same authors reported decreased prevalence and incidence of atrial fibrillation (AF) in the T3-treated cohort monitored beyond 24 h w8x. Significantly, fewer required rate and rhythm control, or anticoagulation therapy although there was no significant difference in presence of AF at discharge w8x.
Cimochowski et al. administered T3 as part of a complex combination of metabolic and mechanical support strategies in patients with severe LV dysfunction w9x. Inotrope requirement, operative mortality, stroke and renal failure were significantly lower in their intervention group although it is clearly impossible to separate T3-effects from other interventions.
Other studies have failed to demonstrate improvements in cardiac output let alone other outcome markers. Guden et al. found no significant differences in post-CPB haemodynamic parameters, dysrhythmia incidence, need for inotropic support, ITU stay and morbidity or mortality in patients receiving T3 w5x. Bennett-Guerrero et al. could demonstrate no beneficial effects of T3 on perioperative haemodynamics compared to Dopamine or placebo in patients at high risk of requiring post-CPB inotrope support w6x. Requirement for pacing in the first 6 h was significantly greater in the T3 and placebo patients but requirement for IABP or inotropes between groups was not significant. There was no difference in time to extubation, time in ITU or to hospital discharge, or other morbidity and mortality between groups w6x. Finally, Teiger et al. were unable to demonstrate significant differences in haemodynamic parameters in a small group given T3 at cross-clamp removal w10x.
A number of different doses of T3 or Thyroxine are described. Whilst some authors justify their dose rationale w2,3,6,10,13x, others do not w4,5,7,12,14x and it may well be that the optimal dosing regime has not been described. It may also be noteworthy that most studies have been performed in patients with LV impairment w2-4,6,8-14x. One study has reported sex-dependant haemodynamic responses to T3 although outcome measurements were similar w7x. T3 has also been described as rescue therapy in various case series involving high risk cases undergoing cardiac surgery. In 1989 Novitzky et al. gave T3 to 10 patients difficult to wean from CPB and demonstrated significant improvements in cardiac function with decreased IABP or inotrope support w11x. The same author subsequently reported another 68 cases given various T3 doses with similar decreases in mortality compared to predicted not only in their overall group but also in a subset of 12 patients remaining 'unexpectedly' CPB-dependant w12x. Malik et al. successfully bridged 9 out of 10 patients with severe cardiogenic shock to LVAD or heart transplantation using IV Thyroxine w13x. Finally, Carrel et al. reported various T3 regimes in post-CPB, brain dead or pre-transplant patients showing apparent improvements in cardiac function w14x. However, their inhomogeneous series lacked consistent management protocolsyuniformity of dosage regimes and their data were not subjected to statistical analysis.
Clinical bottom line
Thyroxine levels decrease significantly during Cardiopulmonary bypass. However, there is conflicting evidence that prophylactic perioperative thyroxineytriiodothyronine is a useful adjunct in adult patients undergoing cardiac surgery. Whilst some papers report improved haemodynamic parameters in the immediate post-bypass period, there is no standardised dose or evidence that its use decreases postoperative morbidity, mortality or length of stay in the routine patient. It may, however, still be useful as rescue therapy in weaning some high risk cases from CPB or bridging them to LVAD or transplant.
